Additionally, a global, multicenter, randomized, double-blind, phase 3 REACH study proved that AFP could be a predictive marker for ramucirumab (a second-line treatment in patients with advanced HCC) survival benefit [15]. Here, AFP is linked to hepatocellular carcinoma.